Market Leadership Hemosure®'s Fecal Occult Blood test (iFOB) has maintained its #1 position in the US for nearly a decade, demonstrating strong brand loyalty and high demand among healthcare providers, which provides opportunities to expand product offerings and related diagnostic solutions.

Innovative Automation The FDA-cleared Hemosure® Accu-Reader A 100 system offers automated, rapid, and reliable fecal occult blood testing, catering to clinics and labs seeking efficiency improvements, creating potential for upselling or complementary devices.

Growth Potential With a revenue range of 10 to 25 million dollars and a focus on gastrointestinal diagnostics, there is an opportunity to target mid-sized medical facilities and laboratories that are investing in high-quality, automated testing technologies.

Strategic Location Located near Los Angeles, Hemosure® benefits from proximity to leading medical professionals and institutions, opening doors for partnership development, pilot programs, and expanding reach within prestigious healthcare networks.

Industry Alignment Hemosure® operates within a competitive landscape alongside industry giants like Abbott and Thermo Fisher Scientific, indicating potential to differentiate through customized solutions, superior quality, and personalized service to attract niche market segments.